- POSITIVE
Annual Revenue Hemant Surgical Mar-2026 Annual Revenue is Rs 237 Cr which is growth of 112.0% YoY.
- POSITIVE
Annual Net Profit Hemant Surgical Mar-2026 Annual Net Profit is Rs 18 Cr which is growth of 124.2% YoY.
BSE: 543916
Hemant Surgical Live Share Price Today, Share Analysis and Chart
aboutHemant Surgical Industries Ltd. is a provider of medical equipment and healthcare solutions, primarily focused on the manufacturing and supply of medical devices and consumables. The company serves as a comprehensive player in the medtech industry, c... Read More
579.90-30.50(-5.00%)
20,400
BSE Volume
BSE 18 Nov, 2026 3:31 PM
Hemant Surgical Stock Price Ranges
Day Price Range-5.0% 1 Day return | 579.9 (LTP) 579.9582 LowHigh |
|---|---|
Week Price Range-8.8% 1 Week return | 579.9 (LTP) 579.9670.4 LowHigh |
Month Price Range-1.7% 1 Month return | 579.9 (LTP) 540670.4 LowHigh |
52 Week Price Range103.5% 1 Year return | 579.9 (LTP) 215679 LowHigh |
Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Hemant Surgical annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
28.5% | 31.3% | 236.7 | 111.6 | 109.9 | 111.5 | 105.8 | 60.7 | 56.5 | 56.2 | 50.8 | 51.7 | 39.9 | ||
Operating Exp. Ann. | 28.1% | 29.6% | 207.6 | 97.5 | 95.1 | 98.7 | 97.3 | 56.7 | 53.5 | 53 | 48.1 | 49.1 | 37.3 | |
Operating Profit Ann. | 30.6% | 49.8% | 23.4 | 9.1 | 10.5 | 10.5 | 6.3 | 3.1 | 2.6 | 2.7 | 2.5 | 2.4 | 2.3 | |
OPM Ann. % | 1.7% | 14.3% | 9.88% | 8.13% | 9.53% | 9.39% | 5.96% | 5.07% | 4.57% | 4.77% | 4.88% | 4.70% | 5.83% | |
28.1% | 29.2% | 213.1 | 101.1 | 97.1 | 101.4 | 99.7 | 59.1 | 55.6 | 54.9 | 49.8 | 50.9 | 39.2 | ||
EBITDA Ann. | 31.5% | 48.7% | 29.1 | 14.2 | 14.8 | 12.8 | 8.5 | 4 | 3 | 3.2 | 2.8 | 2.7 | 2.6 | |
EBITDA Ann. margin % | 2.3% | 13.5% | 12.30% | 12.71% | 13.45% | 11.50% | 8.04% | 6.53% | 5.33% | 5.64% | 5.43% | 5.16% | 6.41% | |
Interest Ann. | 28.2% | 17.3% | 4 | 2.2 | 1 | 1.9 | 1.6 | 1.8 | 1.4 | 1.4 | 1.3 | 1.6 | 1.7 | |
Depr. | 18.6% | 20.1% | 1.5 | 1.4 | 1 | 0.9 | 0.8 | 0.6 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | |
PBT Ann. | 32.7% | 73.5% | 23.6 | 10.6 | 12.8 | 10.1 | 6.1 | 1.5 | 1 | 1.2 | 1 | 0.9 | 0.7 | |
Tax Ann. | 31% | 68.3% | 5.4 | 2.4 | 3 | 2.4 | 1.5 | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | |
33.2% | 72.3% | 18.2 | 8.1 | 9.8 | 7.7 | 4.6 | 1.2 | 0.9 | 1.1 | 0.9 | 0.8 | 0.6 | ||
Net Profit Ann. | 33.2% | 72.3% | 18.2 | 8.1 | 9.8 | 7.7 | 4.6 | 1.2 | 0.9 | 1.1 | 0.9 | 0.8 | 0.6 | |
NPM Ann. % | 4.1% | 32.8% | 7.89% | 7.63% | 9.27% | 7.00% | 4.45% | 1.91% | 1.52% | 2.03% | 1.85% | 1.55% | 1.57% | |
EPS Adj. latest Ann. | 33.4% | 73.1% | 14 | 6.2 | 7.5 | 5.9 | 3.5 | 0.9 | 0.7 | 0.9 | 0.7 | 0.6 | 0.5 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
112.1%
2Y CAGR
46.8%
3Y CAGR
28.5%
5Y CAGR
31.3%
7Y CAGR
22.8%
10Y CAGR
19.5%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
124.7%
2Y CAGR
36.3%
3Y CAGR
33.2%
5Y CAGR
72.3%
7Y CAGR
49.3%
10Y CAGR
40.7%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
112.9%
2Y CAGR
47.7%
3Y CAGR
28.1%
5Y CAGR
29.6%
7Y CAGR
21.5%
10Y CAGR
18.7%
Operating Expenses Annual Cr growth is higher than historical averages.
Hemant Surgical Technical Analysis
Hemant Surgical EMA & SMA
Bearish-2
Bullish3
Bearish5
| 5 Day | 613.0 |
|---|---|
| 10 Day | 617.7 |
| 12 Day | 617.1 |
| 20 Day | 611.0 |
| 26 Day | 604.0 |
|---|---|
| 50 Day | 567.3 |
| 100 Day | 503.2 |
| 200 Day | 426.5 |
Hemant Surgical Delivery And Volume
Daily Avg. Delivery Volume %
18 Nov, 2026100.0%
Week100.0%
Month100.0%
PositiveNeutralNegative
Hemant Surgical Resistance and Support
580.60
Pivot
| First Resistance | 581.3 |
|---|---|
| Second Resistance | 582.7 |
| Third Resistance | 583.4 |
| First Support | 579.2 |
|---|---|
| Second Support | 578.5 |
| Third Support | 577.1 |
| Day RSI | 43.7 |
|---|---|
| Day MACD | 13.1 |
| Day MFI | 74.8 |
| Day MACD Signal Line | 17.8 |
Hemant Surgical Beta
| 1 Month | 1.7 |
|---|---|
| 1 Year | 0.7 |
| 3 Month | 0.5 |
|---|---|
| 3 Year | 0.2 |
Hemant Surgical Price Change Analysis
↓-1.7%
Over 1 Month
LowHigh
540670.4
↑62.9%
Over 3 Months
LowHigh
328.4679
↑42.2%
Over 6 Months
LowHigh
328.4679
↑103.5%
Over 1 Year
LowHigh
215679
Hemant Surgical Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| MONA LAROIA | Bulk | Purchase | 22 Aug 2025 | 279.45 | 59,200 | BSE |
| DEVENDRA AGARWAL | Bulk | Sell | 16 Jul 2025 | 189.82 | 75,200 | BSE |
| ROHAN GUPTA | Bulk | Sell | 16 Jul 2025 | 189.82 | 75,200 | BSE |
| SURESH ZUNZUNWALA | Bulk | Purchase | 16 Jul 2025 | 182.64 | 139,200 | BSE |
| MONA LAROIA | Bulk | Purchase | 16 Jul 2025 | 189.70 | 150,400 | BSE |
| SURESH ZUNZUNWALA | Bulk | Purchase | 15 Jul 2025 | 172.57 | 60,000 | BSE |
| SURESH ZUNZUNWALA | Bulk | Purchase | 14 Jul 2025 | 156.31 | 55,200 | BSE |
| GAURISHANKAR JHALANI | Bulk | Purchase | 19 Jul 2024 | 203.83 | 75,200 | BSE |
| SETU SECURITIES PVT. LTD. | Bulk | Sell | 09 Jun 2023 | 158.77 | 60,800 | BSE |
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 09 Jun 2023 | 159.01 | 100,800 | BSE |
Hemant Surgical Corporate Actions
Hemant Surgical Board Meetings
Hemant Surgical past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
114 Nov 2026 | Half Yearly Results | - |
215 May 2026 | Audited Results | - |
312 Nov 2025 | Half Yearly Results | - |
406 Aug 2025 | Preferential issue of shares | - |
528 May 2025 | Audited Results | - |
Hemant Surgical Corporate Filings
Hemant Surgical BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 14 Nov 2026 | Hemant Surgical Industries Ltd - 543916 - Un-Audited Financial Results Of The Company For The Half Year Ended September 30, 2026 | Unaudited Financial Results (standalone and consolidated) of the Company for half year ended September 30, 2026. | |
| 14 Nov 2026 | Hemant Surgical Industries Ltd - 543916 - Board Meeting Outcome for Meeting Held On November 14, 2026 | Unaudited Financial Results (standalone and consolidated) of the Company for half year ended September 30, 2026 | |
| 05 Nov 2026 | Hemant Surgical Industries Ltd - 543916 - Board Meeting Intimation for Considering And Approval Of Unaudited Financial Results Of The Company For The Half Year Ended September 30, 2026 | Hemant Surgical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Unaudited Financial Results Of The Company For The Half Year Ended September 30, 2026 | |
| 07 Oct 2026 | Hemant Surgical Industries Ltd - 543916 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026 | |
| 29 Sep 2026 | Hemant Surgical Industries Ltd - 543916 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Scrutinizer Report and Voting result of AGM held on September 29, 2026 |
Hemant Surgical Documents
Hemant Surgical Credit Ratings
Hemant Surgical credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 08 Apr 2026 | icra ratings | Hemant Surgical Industries Limited | Ratings upgraded to [ICRA]BBB(Stable)/ [ICRA]A3+; rated amount enhanced | Link |
| 21 Jan 2025 | icra ratings | Hemant Surgical Industries Limited | [ICRA]BBB-(Stable)/[ICRA]A3; assigned | Link |
| 14 Oct 2024 | icra ratings | Hemant Surgical Industries Limited | Ratings withdrawn | Link |
| 29 Aug 2024 | icra ratings | Hemant Surgical Industries Limited | Outlook revised to Stable from Positive, continues to remain under issuer Non-Cooperating category | Link |
Hemant Surgical - Company Profile
Hemant Surgical Management Structure
Hemant Surgical management structure with salaries, total experience, and qualifications.
Hemant Surgical Board of Directors
Hemant Surgical Board of directors with salaries, total experience, and qualifications.
Website: www.hemantsurgical.com
About the company - Business Profile
Hemant Surgical Industries Ltd. is a provider of medical equipment and healthcare solutions, primarily focused on the manufacturing and supply of medical devices and consumables. The company serves as a comprehensive player in the medtech industry, catering to various therapeutic areas including dialysis, cardiovascular health, and general surgical procedures. It maintains a role as both a manufacturer and an importer, enabling it to offer a diverse range of specialized medical equipment.
Key Points
- Key Facts:
- Incorporated: 1989 (CIN: L33110MH1989PLC0511333)
- Headquarters: Mumbai, Maharashtra.
- Stock Listing: Listed on the SME platform of BSE (BSE SME).
- Operations and Resources:
- The company operates a manufacturing facility and maintains a logistics network to support its distribution business.
- As of March 31, 2025, the company reported a Net Block (Property, Plant, and Equipment) of ₹3,986.62 Lakhs.
- It acquired a subsidiary on March 13, 2025, leading to consolidated reporting for subsequent periods.
- Business Model and Expertise:
- The company follows a hybrid model of domestic manufacturing and strategic imports.
- It excels in providing end-to-end solutions for renal care (dialysis) and surgical consumables.
- Financial Performance (FY2025 - Annual Numbers):
- Total Standalone Revenue (March 2025): ₹11,163.90 Lakhs.
- Revenue from Operations (Standalone): ₹10,652.66 Lakhs.
- Profit After Tax (Standalone): ₹804.10 Lakhs.
- Profit Before Tax (Standalone): ₹1,046.58 Lakhs.
- Recent Performance (Half-Year Ended September 30, 2025):
- Consolidated Revenue from Operations: ₹6,426.06 Lakhs.
- Consolidated Net Profit: ₹545.98 Lakhs.
- Basic EPS (H1 FY26): ₹5.15.
- Revenue Breakdown:
- The company operates in a single reportable segment: Medical Equipment and Healthcare Solutions.
- Geographical Focus: Primarily domestic (India), with emerging operations in international markets through its distribution channels.
- Key Products and Technology:
- Specializes in Hemodialysis machines, Dialyzers, and related consumables.
- Offers Surgical Sutures, Disposables, and Cardiology products.
- The company focus is on the localization of medical device manufacturing to align with national healthcare initiatives.
- Strategic Initiatives:
- The company recently completed a fund-raising exercise via a Rights Issue or similar capital infusion, as reflected in the increase in share capital from ₹1,044 Lakhs in March 2025 to ₹1,303.84 Lakhs by September 2025.
- Integration of the newly acquired subsidiary to enhance manufacturing capabilities and market reach.
References
